Beta Bionics Secures an Initial $50 Million Series B Round

The round was led by Eventide Asset Management Other institutional investors in Series B include RTW Investments Corporate strategic partner and Series A investor, Novo Nordisk, has also participated in Series B Corporate strategic partner, Zealand Pharm, previously committed $5m to Series B in December 2017 BOSTON, Sept.